Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer

Trial ID #	NCT02440425
Phase	II
Drug Class	Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name	Pembrolizumab
Alternate Drug Names	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial	Paclitaxel, Pembrolizumab
Eligible Participant	Platinum resistant ovarian cancer
Patients Enrolled	37
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, PFS, OS, evaluated per RECIST
Efficacy	ORR: 51.4% PFS: 6.7 months OS: 13.4 months PFS (6 months): 52.5%
Conclusion	Pembrolizumab+paclitaxel shows improved ORR and PFS compared to historical results with paclitaxel
Reference	Wenham RM et al. Phase 2 trial of weekly paclitaxel with pembrolizumab in platinum resistant recurrent ovarian cancer. Intl J Gynecol Cancer (2018) 28 (Suppl 2) 1-1258 Combinations Will Lead the Way in Immunotherapy for Ovarian Cancer, Onc LIve SGO WInter Meeting Conference Coverage, 2/10/2020 https://www.clearityfoundation.org/wp-content/uploads/2020/02/Combinations-Will-Lead-the-Way-in-Immunotherapy-for-Ovarian-Cancer.pdf